Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Systemic mastocytosis is a rare disease of mast cell proliferation.
• The KIT receptor tyrosine kinase is crucial for mast cell development and survival.
• Activating KIT mutations, particularly D816V, are prevalent in systemic mastocytosis.

Purpose of the Study:

• To review the role of KIT mutations in systemic mastocytosis.
• To discuss the evolution of tyrosine kinase inhibitors (TKIs) for mastocytosis treatment.
• To highlight the impact of novel TKIs on managing D816V-mutated mastocytosis.

Main Methods:

• Literature review of systemic mastocytosis pathogenesis and treatment.
• Analysis of studies on KIT mutations and TKI efficacy.
• Examination of clinical trial data for midostaurin and avapritinib.

Main Results:

• Activating KIT mutations are key drivers in most systemic mastocytosis cases.
• Early TKIs showed limited efficacy, primarily in D816V-negative patients.
• Newer TKIs, including midostaurin and avapritinib, demonstrate activity against the D816V KIT mutation.

Conclusions:

• Targeting KIT is a rational therapeutic strategy for systemic mastocytosis.
• Advances in TKI development have significantly improved treatment options for patients with the common KIT D816V mutation.
• The therapeutic landscape for systemic mastocytosis has been transformed by novel KIT-targeted agents.